the major route for their elimination (20, 35) . These excretory pathways play an important role in preventing nephrotoxicity (9, 11, 35) . Kidneys and especially renal proximal tubules are most sensitive to the toxic cysteine S-conjugates (2, 7, 10, 21, 26) .
In kidneys, mercapturic acids can be secreted into urine by proximal tubules (2, 7, 10, 21, 26) . Localized to the basolateral membrane of S1, S2, and S3 proximal tubules (25, 39) , the organic anion transporter 1 (OAT1) was recently shown to mediate the cellular influx of mercapturic acids into proximal tubule cells (34) . The organic acid transporter OAT3 has overlapping substrate specificity and is probably involved in this process as well (5) . Masereeuw et al. (31) have shown that mercapturic acids can be secreted through the brush-border membrane into urine using the multidrug-resistance-associated protein (MRP2) and/or diffusion.
Mercapturic acids may become nephrotoxic in a sequence of reactions catalyzed by aminoacylase and ␤-lyase. In general, the product of the deacetylation reaction is not toxic; however, it becomes toxic in a subsequent reaction that is catalyzed by cysteine S-conjugate ␤-lyase (2, 7-10, 23, 24, 38, 40) , which is localized to mitochondria. Mitochondria are especially vulnerable to toxic cysteine S-conjugates (17, 32) . However, despite the fact that the mitochondrial mass is greatest in S1 tubules (12) , many cysteine S-conjugates are more toxic for S2 and S3 proximal tubule segments (22, 23, 32, 46) . The variation among proximal tubule segments in sensitivity to cysteine S-conjugates may be due to differences in the intracellular distribution and characteristics of ␤-lyase and aminoacylase among proximal tubule segments. ␤-Lyase is uniformly expressed in all three segments of proximal tubule and is therefore not likely responsible for the variation in toxicity (23, 24, 30) . There are two aminoacylases that could contribute to the nephrotoxicity to cysteine S-conjugates. Aminoacylase I (EC 3.5.1.14, N-acetylamino acid hydrolase) has been shown to catalyze the deacetylation of (1, 16, 18, 27, 28, 42, 43) . However, the aminoacylase I transcript, similar to ␤-lyase, is uniformly expressed throughout proximal tubules (29) . Therefore, aminoacylase I is unlikely responsible for the variation in toxicity among proximal tubule segments.
neutral aliphatic N-acyl-␣-amino acids including N-acetyl-L-cysteine, N-acetyl-S-(1,1,2,2-tetrafluoroethyl)-L-cysteine, N-acetyl-S-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine, N-acetyl-S-(2-bromo-1,1,2-trifluoroethyl)-Lcysteine, and several S-alkyl-N-acetylcysteines
An aminoacylase that preferentially catalyzes the deacetylation of N-acetylaromatic amino acids has been partially purified from rat liver cytosol (36) and rat kidney (13, 42) . In addition, this partially purified enzyme catalyzes N-deacetylation of some S-aryl-and S-aralkylmercapturic acids including 2,3,4 ,4-pentaclorobutadienyl)-L-cysteine, and N-acetyl-S-benzyl-L-cysteine, and is therefore also a potential candidate for mediation of the nephrotoxicity of some mercapturates. However, the molecular identity of this aminoacylase is currently unknown. Given its potential role in mediating the nephrotoxicity of mercapturates and the deacetylation of N-acetyl-S-aromatic amino acids, a goal of the present study was to clone the enzyme, characterize its functional properties, and determine its oligomeric structure and localization in kidney.
MATERIALS AND METHODS
All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of California, Los Angeles.
Cloning of mouse kidney aminoacylase III. The coding sequence for aminoacylase III was identified by searching the mouse Expressed Sequence Tag database (dbEST) for homology with mouse aminoacylases I and II. Several overlapping dbEST clones were identified in the house mouse (Mus musculus) database with homology to aminoacylase II. We identified an IMAGE clone (4155233, Invitrogen, San Diego, CA) that contained the complete open reading frame of aminoacylase III. To confirm that the mouse aminoacylase III sequence was derived from a bona fide transcript, we amplified the entire open reading frame via PCR using mouse kidney cDNA (Clontech, Palo Alto, CA). Nucleotide sequences were determined bidirectionally using automated sequencing (ABI 310, Perkin Elmer, Foster City, CA).
Northern analysis. Northern blots with various mouse tissues were obtained from Origene (Rockville, MD). The probe was random prime labeled with [ 32 P]dCTP to a specific activity of ϳ1.5 ϫ 10 9 dpm/g. The filters were prehybridized at 42°C for 2 h using 50% formamide, 6ϫ standard saline phosphate EDTA (SSPE), 0.5% SDS, Denhardt's solution, and 0.1 mg/ml sheared herring testes denatured DNA. After the prehybridization, filters were incubated with the 32 P probe using 25 ml of hybridization buffer. The probe was denatured and added to the hybridization solution at 10 7 dpm/ml. The filters were probed at 42°C for 18 h and washed in 1ϫ SSC (0.15 M NaCl in 15 mM sodium citrate), 0.1% SDS at 45°C for 60 min (4 changes, 400 ml/wash) and were exposed on BioMax MS film (Eastman Kodak, Rochester, NY). The probe used to identify mouse aminoacylase III was a 226-bp PCR product. The following primers were used: sense, 5Ј-GAAGCACGTGGCATTCCTGAAGT-3Ј; antisense, 5Ј-GGGGCACAGTCTATTTTATATAATGAGAT-3Ј.
Generation and characterization of polyclonal antibodies to mouse aminoacylase III. A polyclonal antibody to mouse aminoacylase III (MR-C1) was raised in rabbits against a synthetic peptide derived from the COOH terminus of the protein corresponding to amino acids 302-317 in mouse aminoacylase III coupled to an NH 2-terminal cysteine. The antibody was affinity purified using Sepharose 4B columns with a covalently attached aminoacylase III peptide. This antibody identified an ϳ35-kDa band upon SDS-PAGE of mouse kidney homogenates and mouse kidney microsomal membranes, and an ϳ38-kDa band in extracts from human embryonic kidney (HEK)-293 cells that expressed His-tagged mouse aminoacylase III (Fig. 1) . Penta-His antibody from Qiagen (Valencia, CA) yielded an identical size for the His-tagged fusion aminoacylase III that was expressed in HEK-293 cells (Fig. 1) .
Purification of mouse aminoacylase III from HEK-293 cells. The coding region of aminoacylase III was inserted into the BamHI-XhoI site of a pcDNA3.1-His vector (Invitrogen, Carlsbad, CA). The construct was expressed as a His6-tagged fusion protein in HEK-293 cells. The cells (ϳ1 g) were collected 24 h after transfection, washed three times with PBS (10 mM sodium phosphate, pH 7.4, that contained 140 mM NaCl), and suspended in 20 ml of 50 mM Tris⅐HCl buffer that contained 1% Triton X-100 and the following protease inhibitors: 1 mM PMSF, 1 mM EDTA, 1 g/ml pepstatin, 1 g/ml leupeptin, and 1 g/ml aprotinin (all protease inhibitors were from Roche, Indianapolis, IN). After the homogenate was incubated for 30 min, it was centrifuged at 18,000 ϫg for 20 min at 4°C. The supernatant was dialyzed for 16 h at 4°C against PBS and purified on a Ni-superflow resin (Novagen, Madison, WI) column (2 ϫ 8 cm) according to the manufacturer's protocol. The fractions that contained His6-tagged aminoacylase III were combined, dialyzed against 20 mM Tris⅐HCl, pH 7.5, and loaded into a 3 ϫ 6-cm column of DEAE-cellulose DE52 (Whatman, Maidstone, Kent, UK) equilibrated with the same buffer. The proteins were eluted onto a 0-250 mM Tris⅐HCl gradient. Fractions that contained aminoacylase III were combined and then concentrated and transferred to PBS using a Centriplus YM-10 centrifugal filter device (Millipore, Bedford, MA). All purification procedures were performed at 4°C. SDS-PAGE and Western blotting ( Fig. 1) showed one protein band that reacted with both mouse kidney aminoacylase III-specific MR-C1 and penta-His antibodies. The size of the purified fusion protein was ϳ38 kDa, which is in good agreement with the size predicted based on the amino acid composition for mouse kidney aminoacylase III (ϳ35 kDa) plus ϳ3 kDa for the His6 tag.
The His6-containing vector sequence of ϳ3 kDa fused with the NH 2 terminus of mouse kidney aminoacylase III could potentially affect the kinetic characteristics and the oligomeric structure of the enzyme. Therefore the fusion protein was treated with a recombinant enterokinase (Novagen) to hydrolyze the enterokinase site between the vector and the NH 2-terminal coding region of the enzyme. After digestion was completed (as determined by SDS-PAGE and Western blotting with the mouse kidney aminoacylase III-specific and pentaHis antibodies; see Fig. 1B ), the enterokinase was absorbed on enterokinase capture beads (Novagen). The untagged aminoacylase III was used in all experiments.
Purification of aminoacylase III from mouse kidney. Mouse kidneys (ϳ1 g) were disrupted in a glass homogenizer in 50 ml of 50 mM Tris⅐HCl buffer that contained 1% Triton X-100 and the following protease inhibitors: 1 mM PMSF, 1 mM EDTA, 1 g/ml pepstatin, 1 g/ml leupeptin, and 1 g/ml aprotinin. After 45 min of incubation, the homogenate was centrifuged at 18,000 g for 20 min at 4°C. The supernatant was dialyzed overnight against 50 mM Tris⅐HCl, pH 7.5, that contained the protease inhibitors and was loaded on a DEAEcellulose column equilibrated with the same buffer. Proteins were eluted onto a 0-0.3 M linear gradient of NaCl in 50 mM Tris⅐HCl, pH 7.5. Fractions that contained aminaocylase III (detected by Western blotting with aminoacylase III-specific antibody MR-C1) were combined, concentrated on a Microcon 10 filter device (Amicon, Beverly, MA) and used for the molecular mass determination of aminoacylase III via size-exclusion chromatography.
Microsomal membrane isolation from mouse kidney. Mouse kidneys (ϳ2 g) were disrupted in a glass homogenizer in 100 ml of 50 mM Tris⅐HCl, pH 7.5, that contained 5% sucrose and the following protease inhibitors: 1 mM PMSF, 1 mM EDTA, 1 g/ml pepstatin, 1 g/ml leupeptin, and 1 g/ml aprotinin. The homogenate was centrifuged at 300 g for 10 min, and the supernatant was centrifuged at 4,000 g for 10 min and then at 18,000 g for 15 min. The resulting supernatant was centrifuged at 105,000 g for 2 h. The pellet was suspended in the buffer used for homogenization and centrifuged at 105,000 g for 1 h. This step was repeated twice. The final pellet was analyzed by SDS-PAGE and Western blotting using the aminoacylase III-specific antibody MR-C1.
SDS-PAGE and Western blotting. SDS-PAGE was performed using a 10-20% gradient of polyacrylamide Ready Gels (Bio-Rad, Hercules, CA). Proteins separated by SDS-PAGE were electrotransferred onto PVDF membrane (Amersham Biosciences, Piscataway, NJ). Nonspecific binding was blocked by incubation for 1 h in Tris-buffered saline (TBS: 20 mM Tris⅐HCl, pH 7.5, 140 mM NaCl) that contained 5% dry milk and 0.05% Tween 20 (Bio-Rad). The MR-C1 aminoacylase III-specific antibody and mouse penta-His antibody were used at dilutions of 1:2,000 and 1:5,000, respectively. Secondary horseradish peroxidase-conjugated species-specific antibodies (Jackson Immunoresearch, West Grove, PA) were used at a dilution 1:20,000. Bands were visualized using an ECL kit and Hyperfilm ECL (Amersham Biosciences).
Aminoacylase III functional assay. Aminocylase III activity was determined with different N-acetylated amino acids by measuring the amount of a deacetylated product that was formed in a fluorescence assay (41) . The reaction mixture in a total volume of 0.2 ml contained 50 mM sodium phosphate buffer, pH 7.5, N-acetylated amino acid, and the enzyme. After incubation at 37°C for 30 min, the reaction was stopped by addition of trichloroacetic acid to a final concentration of 5%. The mixture was centrifuged 10 min later at 12,000 g for 5 min, and 1.8 ml of 50 mM sodium phosphate was added to the supernatant. After addition of 150 l of fluorescamine solution (10 mg in 33 ml of acetone), fluorescence measurements (390-nm exitation, 475-nm emission) were performed on an LS-5 fluorescence spectrophotometer (Perkin Elmer, Norwalk, CT). Separate calibration curves were created and used for quantitation of every amino acid product.
Size-exclusion chromatography. The molecular mass of nondenatured mouse aminoacylase III purified from HEK-293 cells overexpressing the enzyme or from mouse kidney was determined on a 1 ϫ 80-cm column of Sephacryl S-200 (Amersham Biosciences) equilibrated with PBS. The recombinant aminoacylase III was untagged before it was used for the molecular mass determination. The column was calibrated with carbonic anhydrase (30 kDa), ovalbumin (43 kDa), bovine serum albumin (67 kDa), lactate dehydrogenase (140 kDa), and catalase (232 kDa). All size markers were purchased from Amersham Biosciences.
Electron microscopy and image analysis. Transmission electron microscopy was performed on a JEM-1,200EX electron microscope (Jeol, Tokyo, Japan) at 80 kV with magnification of ϫ74,440. The magnification was calibrated with orthorhombic catalase crystals. The purified untagged recombinant aminoacylase III was used for electron microscopy. The enzyme was negatively stained with 1% uranyl acetate using a single carbon technique (44) . A Bioscan 600W digital camera (Gatan, Pleasanton, CA) was used to record the images. The image analysis was performed on an SGI Origin 3800 computer in the Supercomputer Institute at the University of Minnesota using SPIDER (System for Processing Image Data in Electron Microscopy) software (14, 15) . Protein images of the same size (128 ϫ 128 pixels) that contained individual squarelike projections of protein were selected interactively for digital alignment and averaging from the images displayed on the monitor screen. A circular mask was imposed upon selected images to remove unnecessary background, and each selected image was floated within this mask using the averaged density and Gaussian filter (15) . The final step involved alignment and averaging of selected projections to increase the signal-to-noise ratio (14) . Because individual protein images had different translational and rotational orientations, their images could be aligned using relative translation and rotation before averaging using one particle as a reference image (15) . However, it has been shown that the use of a reference particle or model for alignment of a population of particles can bias the result of averaging toward the reference image (3). To exclude bias, a reference-free alignment procedure (33) , which was implemented within the SPIDER software system, was used in this study.
Immunocytochemistry. Mouse kidneys were removed, immediately frozen in liquid nitrogen, and cut into 5-m sections. The MR-C1 aminoacylase III-specific antibody was applied at a 1:100 dilution in PBS for 1 h at 37°C to cryostat sections attached to Probe On Plus glass slides (Fisher, Los Angeles, CA). After several washes in PBS, goat anti-rabbit IgG conjugated with Alexa 594 (a 1:500 dilution, Molecular Probes, Eugene, OR) was applied for 1 h at 37°C. The slides were rinsed in PBS and mounted in Cytoseal 60 (Stephens Scientific, Riverdale, NJ). The confocal images were captured with a Leica TCS SP inverted confocal microscope using a krypton laser (model 643, Melles Griot, Irvine, CA).
RESULTS
The amino acid composition of mouse aminoacylase III is shown in Fig. 2 . The enzyme consists of 318 amino acids and has an estimated minimum molecular mass of 35,188 Da. The deduced amino acid sequence showed 43 and 5% identity with mouse aminoacylase II and mouse aminoacylase I, respectively. The enzyme has consensus sites (on the Internet, see http://www.expasy.org/cgi-bin/scanprosite) for N-glycosyla- ). The hydrophobicity analysis (on the Internet, see http://sosui.proteome. bio.tuat.ac.jp/sosui_submit.html) predicted that the enzyme is a cytoplasmic protein without transmembrane segments (data not shown). Aminoacylase III is encoded by mouse chromosome 19.
The expression of aminoacylase III in mouse tissues was studied using Northern blotting (Fig. 3 ). An ϳ1.4-kb transcript was detected that was expressed predominantly in kidney and to a lesser extent in liver. Transcripts were also detected at a significantly lower level in heart, small intestine, brain, lung, testis, and stomach. In testis, an additional transcript of ϳ2.2 kb was detected that was expressed equally with the ϳ1.4-kb transcript. Immunocytochemistry studies of mouse kidney indicated that the enzyme was localized predominantly in the apical membrane of cells in the S1 segment (Fig. 4) . In subcellular fractionation experiments of mouse kidney, ϳ10% of aminoacylase III was membrane associated (see Fig. 1C ). In proximal straight tubules (S2 and S3 segments), the enzyme was expressed diffusely throughout the cytoplasm (Figs. 5  and 6 ).
SDS-PAGE and Western blotting of mouse kidney homogenates revealed an ϳ35-kDa band (see Fig. 1 ) of mouse kidney aminoacylase III. The untagged recombinant enzyme purified to homogeneity from HEK-293 cells had the same size (see Fig. 1 ). To determine the oligomeric structure of the enzyme, size-exclusion chromatography and transmission electron microscopy were used. Figure 7 illustrates a typical separation of the untagged recombinant purified mouse aminoacylase III and aminoacylase III purified from mouse kidney on a Sephacryl S-200 column. In both cases, a single protein peak was detected that corresponded to a globular protein with molecular mass of ϳ140 kDa. The distribution of the enzymatic activity was identical to the distribution of the recombinant protein density, which indicates that this peak belongs to the enzyme. A comparison of this value with the minimum molecular mass determined by SDS-PAGE suggested that the enzyme is a homotetramer.
A tetrameric structure for the enzyme was further confirmed using transmission electron microscopy. Figure 8A illustrates a typical electron micrograph of negatively stained molecules of the untagged purified mouse kidney aminoacylase III. Squareshaped molecular projections of ϳ9 nm were most frequently seen. Representative molecular projections selected for image processing are shown in Fig. 8B . A computer-averaged image of these projections after reference-free alignment shows four protein densities arranged with a fourfold rotational symmetry (Fig. 8C) , which suggests that the aminoacylase III molecule consists of multiples of four monomers. However, the molecular mass of the enzyme determined by size-exclusion chromatography (130-140 kDa) and estimated molecular mass of the monomer of mouse aminoacylase III of ϳ35 kDa (from SDS-PAGE data and the amino acid composition) indicate that a fourfold rotational symmetry is consistent only with a tetrameric structure of the molecule.
The kinetic characteristics of mouse aminoacylase III expressed in HEK-293 cells and purified to homogeneity are shown in Table 1 . The enzyme used as a substrate the Nacetylated L-aromatic amino acids tyrosine, phenylalanine, and tryptophan, similar to aminoacylase III partially purified from rat kidney (13) and rat liver (36) . The enzyme had higher affinity to S-benzyl-N-acetylcysteine than the purified rat kidney aminoacylase (42) . N-acetylcysteine (a substrate of aminoacylase I) and N-acetylaspartate (a substrate of aminoacylase II or aspartoacylase) were not hydrolyzed by mouse aminoacylase III. Therefore, homogeneous recombinant mouse acylase III has substrate specificity similar to partially purified aminoacylases from rat kidney and liver. Mouse aminoacylase III has a pH optimum (with S-benzyl-N-acetylcysteine and N-acetyltyrosine) of ϳ7.5-7.7, which is similar to partially purified rat liver and kidney aminoacylases (13, 36) . Absence of significant kinetic differences between purified recombinant murine aminoacylase III expressed in HEK-293 cells and partially purified aminoacylase from rat kidney (13) and rat liver (36) indicates that the enzyme used in this study was not modified during the purification procedure and suggests that it should be structurally identical to native aminoacylase III.
DISCUSSION
The cloning and characterization of mouse aminoacylase III provide an opportunity to evaluate the characteristics of this enzyme, which preferentially catalyzes the N-acetylation of N-acyl aromatic amino acids. Although previous studies have characterized partially purified aminoacylase from rat liver (36) and rat kidney (13, 42) , the potential role this enzyme plays in generating nephrotoxic products derived from mercapturates in proximal tubules will be more completely understood given that its primary and oligomeric structures are now known. In this regard, the cloned enzyme provides a potentially important therapeutic target to prevent the nephrotoxicity of various haloalkene-and hydroquinone-derived mercapturates.
Mouse aminoacylase III is a homotetramer of ϳ140 kDa that consists of monomers of ϳ35 kDa. Similar to this finding, partially purified rat liver aminoacylase had a molecular mass of 145 kDa and consisted of monomers of ϳ35 kDa (36) . In contrast, partially purified rat kidney aminoacylase had a molecular mass of 55 kDa (13, 42) and a monomer molecular mass of 33 kDa (42). These differences may reflect real differences in oligomeric structure between the enzymes from different species or the possible effects of isolation and purification conditions. In this regard, our findings are more compatible with the data previously obtained from rat liver (36) . The oligomeric structure of murine aminoacylase III might be important for the regulation of its enzymatic activity. Nevertheless, a deviation from Michaelis kinetics was not detected in this study, which suggests that there is no interaction of monomers in mouse aminoacylase III that affects the binding of the substrates to the enzyme.
The mercapturates of nephrotoxic cysteine S-conjugates are not substrates for mitochondrial ␤-lyase because of a blocked amino group and therefore require deacetylation before ␤-lyase-mediated activation. It was previously hypothesized that the efficiency of the deacetylation reaction in different parts of the nephron could determine the nephrotoxic effects of a given mercapturate (10) . Because it has been shown that ␤-lyase is nearly uniformly distributed in S1, S2, and S3 segments of proximal tubules (10, 23) , this enzyme cannot be responsible for the varying degree of nephrotoxicity among these segments. Our immunolocalization data suggest that aminoacylase III is a potential candidate for mediation of the nephrotoxic effects of certain cysteine S-conjugates.
In S1 tubules, the enzyme was localized predominantly to the apical membrane, whereas in proximal straight tubules, the enzyme was localized in the cytoplasm. The predominant apical localization of aminoacylase III in the S1 segment is a potential clue that can explain the higher resistance of this nephron segment to certain mercapturic acids. Although speculative, the spatial localization of the enzyme may protect S1 mitochondria by 1) decreasing the likelihood that cysteine S-conjugates are bioactivated by mitochondrial cysteine Sconjugate ␤-lyase to nephrotoxic reactive thiols; and/or 2) Values are means Ϯ SE. maintaining a favorable cell-to-lumen mercapturic acid concentration gradient, thereby enhancing the lumenal influx of mercapturic acids via MRP2. The latter mechanism requires that the enzyme is localized to the lumenal side of the apical membrane as, for example, ␥-glutamytransferase, which is anchored to the brush border through a hydrophobic NH 2 -terminal domain (37) . Hydrophobicity analysis of aminoacylase III indicates that the enzyme lacks a potential transmembrane segment, which suggests that the mechanism for its apical localization in S1 cells involves its interaction with one or more apically localized proteins.
